Date: 2016-04-19
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: OncoMed Pharmaceuticals (USA - CA)
Product: GITRL-Fc
Action
mechanism: fusion protein.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 19, 2016, OncoMed Pharmaceuticals presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the FDA for its GITRL-Fc candidate in late 2016/early 2017. In two poster presentations, OncoMed researchers highlighted the differentiating characteristics and preclinical efficacy of this therapeutic candidate. OncoMed's GITRL-Fc is engineered using a novel single-gene linkerless GITR ligand trimer that binds to glucocorticoid-induced tumor necrosis factor receptor. GITRL-Fc appears to act by increasing effector T-cell activation and proliferation and reducing regulatory T-cell mediated immune suppression, resulting in a potent Th1 immune response. Single-agent GITRL-Fc demonstrated profound anti-tumor activity in multiple syngeneic mouse tumor models and achieved statistically significantly greater anti-tumor activity compared with GITR agonist antibody. Notably, GITRL-Fc did not induce the broad release of cytokines in the plasma and spleen observed with the GITR agonist antibody, suggesting the potential for an improved safety profile relative to agonist antibodies. The activity of GITRL-Fc was also studied in comparison and in combination with anti-PDL1 and anti-PD1. GITRL-Fc combined with either anti-PDL1 or anti-PD1 resulted in a number of complete tumor regressions and single-agent GITRL-Fc demonstrated greater anti-tumor activity than single-agent anti-PDL1 or anti-PD1. The anti-tumor activity of GITRL-Fc in combination with either anti-PDL1 or anti-PD1 reduced tumor growth beyond that of any of the agents alone. Mice "cured" with GITRL-Fc or GITRL-Fc/anti-PDL1 or GITRL-Fc/and-PD1 combination treatments were protected from re-challenge with parental tumor cells, indicating the development of sustained anti-tumor immunologic memory. These data were presented in Abstract #2214 "GITR ligand fusion protein (GITRL-Fc) induces T cell mediated anti-tumor immune response and can combine with anti-PDL1 to enhance anti-tumor immunity and long-term immune memory" and Abstract 3215 "GITRL-Fc can significantly reduce tumor growth by stimulating innate and adaptive immunity".
